Clinical Trial Update: Pemetrexed in Patients With Advanced Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 trial evaluating pemetrexed in patients with advanced neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED